"Agreed, for a company with so many growth opportunities ahead of it funds are better spent pursuing these as aggressively as possible."
What can the company spend that $50m on right now, to get a better return for investors that they can't currently do with the existing $200-300m in the bank? Your comments about SBB completely miss the key point that an effective SBB depends on the markets relative valuation at that time! Your comments may apply to Mega cap companies who buy their shares back at all time highs and they don't really pay attention to whether the shares represent good value at the time or not.
The costs associated with the clinical development program will be phased and largely are dicated by the pace of which the FDA moves. In the meantime we're cash flow positive, too. With the figures provided by the company we would be able to run virtually unlimited preclinical and Phase 2 programs for NNZ-2591.
NEU Price at posting:
$14.48 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)